thalidomide has been researched along with Central Hypothyroidism in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 7.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM)." | 5.62 | Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. ( Qureshi, A; Rhee, JH, 2021) |
| " Central hypothyroidism is a well-recognized side effect of bexarotene." | 4.89 | Thyroid dysfunction as an unintended side effect of anticancer drugs. ( Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F, 2013) |
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 3.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid-stimulating hormone secretion and thyroid hormone metabolism have also been described." | 2.47 | Thyroid dysfunction from antineoplastic agents. ( Hamnvik, OP; Larsen, PR; Marqusee, E, 2011) |
| "Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM)." | 1.62 | Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. ( Qureshi, A; Rhee, JH, 2021) |
| "Hypothyroidism is an often underreported complication of cancer treatment." | 1.35 | Hypothyroidism: a growing complication of cancer treatment. ( Kurtin, SE, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Qureshi, A | 1 |
| Rhee, JH | 1 |
| Torino, F | 1 |
| Barnabei, A | 1 |
| Paragliola, R | 1 |
| Baldelli, R | 1 |
| Appetecchia, M | 1 |
| Corsello, SM | 1 |
| Iams, WT | 1 |
| Hames, ML | 1 |
| Tsai, JP | 1 |
| Dahlman, KB | 1 |
| Talbott, MS | 1 |
| Richards, KL | 1 |
| Reddy, NM | 1 |
| Okamura, I | 1 |
| Ikeda, T | 1 |
| Sato, K | 1 |
| Kimura, F | 1 |
| Kurtin, SE | 1 |
| Hamnvik, OP | 1 |
| Larsen, PR | 1 |
| Marqusee, E | 1 |
| de Savary, N | 1 |
| Lee, R | 1 |
| Vaidya, B | 1 |
| Dimopoulos, MA | 1 |
| Eleutherakis-Papaiakovou, V | 1 |
| Horiuchi, R | 1 |
| Yamamoto, K | 1 |
| Chowta, MN | 1 |
| Chowta, NK | 1 |
| Bermúdez Rodríguez, A | 1 |
| Palazuelos Blanco, LR | 1 |
| González Díaz, CI | 1 |
| Amado Señarís, JA | 1 |
| Menon, S | 1 |
| Habermann, T | 1 |
| Witzig, T | 1 |
| Badros, AZ | 1 |
| Siegel, E | 1 |
| Bodenner, D | 1 |
| Zangari, M | 1 |
| Zeldis, J | 1 |
| Barlogie, B | 1 |
| Tricot, G | 1 |
| Lewis, HB | 1 |
| Albert-Recht, F | 1 |
| Walker, W | 1 |
4 reviews available for thalidomide and Central Hypothyroidism
| Article | Year |
|---|---|
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2013 |
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antica | 2011 |
Adverse effects of thalidomide administration in patients with neoplastic diseases.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II | 2004 |
[Hypothyroidisms induced by drugs].
Topics: Amiodarone; Anti-Arrhythmia Agents; Antithyroid Agents; Endocrine Disruptors; Humans; Hypothyroidism | 2006 |
1 trial available for thalidomide and Central Hypothyroidism
| Article | Year |
|---|---|
Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2015 |
9 other studies available for thalidomide and Central Hypothyroidism
| Article | Year |
|---|---|
Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide.
Topics: Aged; Humans; Hyponatremia; Hypothyroidism; Male; Thalidomide; Thyrotropin; Thyroxine; Triiodothyron | 2021 |
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyro | 2015 |
Hypothyroidism: a growing complication of cancer treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Hypothyroidism; Incidence; Iodide Per | 2009 |
Severe hypothyroidism after thalidomide treatment.
Topics: Humans; Hypothyroidism; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2004 |
Hypothyroidism caused by thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Multiple Myeloma; Obesity; Thalidomi | 2006 |
[Thalidomide-induced hypothyroidism].
Topics: Aged; Female; Humans; Hypothyroidism; Immunosuppressive Agents; Thalidomide | 2007 |
Lenalidomide-associated hypothyroidism.
Topics: Antineoplastic Agents; Female; Humans; Hypothyroidism; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Lar | 2007 |
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
Topics: Adult; Clinical Trials as Topic; Female; Humans; Hypothyroidism; Male; Middle Aged; Multiple Myeloma | 2002 |
Cold haemagglutination disease treated by thalidomide.
Topics: Aged; Blood Protein Disorders; Cold Temperature; Cryoglobulins; Female; Hemagglutination; Humans; Hy | 1968 |